- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04398654
Pulmonary Artery Sensor System Pressure Monitoring to Improve Heart Failure (HF) Outcomes
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Claas Christoph, PhD
- Email: claas@ihf.de
Study Locations
-
-
-
Bad Friedrichshall, Germany
- Recruiting
- SLK-Kliniken GmbH - Klinikum am Plattenwald
-
Bad Nauheim, Germany
- Recruiting
- Kerckhoff-Klinik Forschungs GmbH
-
Bad Oeynhausen, Germany
- Recruiting
- Herz- und Diabeteszentrum NRW
-
Berlin, Germany
- Not yet recruiting
- Deutsches Herzzentrum Berlin
-
Berlin, Germany
- Recruiting
- BG Unfallkrankenhaus Berlin
-
Berlin, Germany
- Recruiting
- Charité Universitätsmedizin (Campus Mitte, Campus Benjamin Franklin)
-
Berlin, Germany
- Recruiting
- Praxis am Spreebogen
-
Berlin, Germany
- Recruiting
- Sana Klinikum Lichtenberg
-
Bielefeld, Germany
- Recruiting
- Klinikum Bielefeld
-
Bonn, Germany
- Recruiting
- Universitätsklinikum Bonn
-
Coburg, Germany
- Recruiting
- Klinikum Coburg
-
Dortmund, Germany
- Recruiting
- St Johannes Hospital Dortmund
-
Dresden, Germany
- Recruiting
- Praxisklinik Herz und Gefäße
-
Eisenach, Germany
- Recruiting
- St. Georg Klinikum
-
Erfurt, Germany
- Recruiting
- Helios Klinikum Erfurt
-
Essen, Germany
- Recruiting
- Universitätsklinikum Essen
-
Essen, Germany
- Recruiting
- St. Elisabeth Krankenhaus, Contilia Herz- und Gefäßzentrum
-
Frankfurt, Germany
- Recruiting
- Universitatsklinikum Frankfurt
-
Gießen, Germany
- Recruiting
- Universitätsklinikum Gießen
-
Hamburg, Germany
- Recruiting
- Universitäres Herz- und Gefäßzentrum Hamburg
-
Hannover, Germany
- Recruiting
- Medizinische Hochschule Hannover
-
Kaiserslautern, Germany
- Recruiting
- Westpfalz Klinikum
-
Karlsburg, Germany
- Recruiting
- Klinikum Karlsburg
-
Köln, Germany
- Recruiting
- St. Vinzenz Hospital
-
Leipzig, Germany
- Recruiting
- Leipzig Heart Institute GmbH
-
Ludwigsburg, Germany
- Recruiting
- Cardio Centrum Ludwigsburg-Bietigheim
-
Oldenburg, Germany
- Recruiting
- Klinikum Oldenburg
-
Recklinghausen, Germany
- Recruiting
- Klinikum Vest
-
Rostock, Germany
- Recruiting
- Cardio Consil Rostock
-
Trier, Germany
- Recruiting
- Krankenhaus der Barmherzigen Brüder
-
Villingen-Schwenningen, Germany
- Recruiting
- Schwarzwald-Baar Klinikum
-
Winnenden, Germany
- Recruiting
- Rems-Murr Klinikum
-
Würzburg, Germany, 97080
- Recruiting
- Deutsches Zentrum für Herzinsuffizienz (DZHI)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written consent received from the patient or a legal representative after the in-formation has been provided.
- ≥≥ 18 years of age.
- Predominant symptoms in NYHA Stage III in the 30-day period prior to consent to the study.
- Objectified HF diagnosis for more than three months.
- Hospitalisation within 12 months prior to inclusion due to deterioration of HF symptoms.
- Able to tolerate dual antiplatelet therapy or anticoagulation therapy for one month after sensor implantation
- Patients with reduced left ventricular ejection fraction (LVEF) ≤40% (diagnosed within 6 months prior to inclusion) must be treated with guideline-compliant HF pharmacotherapy; if one class of guideline-compliant medication is not tolerated, appropriate documentation must be supplied; patients must receive and tolerate at least one class of guideline-compliant medication; if no guideline-compliant medication is tolerated at all, the patient may not participate in the study.
- In patients with preserved LVEF (>40%; diagnosed within 6 months prior to inclu-sion) comorbidities must be treated in accordance with guideline-compliant medi-cation.
- Chest circumference (measured at axillary level) of less than 165 cm if BMI >35 kg/m2.
- Willing and mentally and physically able to meet the requirements for follow-up and long-term basic care (this includes the long-term willingness of the patient, and of their relatives where relevant, to participate in PA pressure-based monitor-ing).
- Appropriate domestic situation, defined as being accessible by telephone (via fixed or mobile network) .
- For the intervention group: Implantation is only performed if the diameter of the pulmonary artery branch intended for implantation is ≥7 mm (assessment will be made during the right heart catheterization)
Exclusion criteria:
- Enrolment in another study with an active treatment arm.
- Severe cardiovascular event (e.g. myocardial infarction, open heart surgery, stroke, CRT implantation) in the 2 months prior to admission
- Therapy-refractory heart failure in ACC/AHA stage D or new therapies that have taken place or are planned in the next 12 months (e.g. implantation of a left ven-tricular assist system / transplantation)
- Active infection.
- History of recurrent (>1 episode) pulmonary embolism and/or deep vein throm-bosis.
- Continuous or intermittent chronic inotropic therapy.
- Estimated glomerular filtration rate (eGFR) <25 ml/min
- Life expectancy (according to the study physician's assessment) <12 months.
- Severe, unrepaired congenital heart defect that would prevent implantation of the sensor.
- Severe valve vitium with planned intervention in the next 3 months
- Presence of a mechanical right heart valve.
- Mental disorder that presumably (in the opinion of the study physician) has a negative impact on patient compliance or consent.
- Failure of the coordinating physician to approve if the patient is enrolled in an HF disease management program or comparable case management program.
- Women of childbearing age with a positive pregnancy test at the time of inclusion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control Group
Monitoring and therapy adjustment within the scope of the basic care described in the clinical trial plan.
|
|
Active Comparator: Intervention Group
As in control group.
In addition, in the intervention arm the CardioMEMSTM HF sensor implanted.
|
CardioMEMSTM HF sensor implantation to meassure pulmonary artery pressure.
Evaluation of the pressure curves by telemetric transmission and coordination of necessary adjustments of the therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary efficacy endpoint: composite of unplanned HF-related rehospitalisations and all-cause death
Time Frame: 12 months
|
Composite endpoint of number of unplanned HF-related rehospitalisations or all-cause death
|
12 months
|
Primary safety endpoint: device-related complications
Time Frame: 12 months
|
Rate of Device / System related complications
|
12 months
|
Co-primary safety endpoint: sensor failure
Time Frame: 12 months
|
Rate of sensor failures
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major secondary endpoint: changes in disease-related quality of life
Time Frame: 6 and 12 months
|
Change in quality of life score after 6 and 12 month measured by Kansas City Cardiomyopathy questionnaire.
Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
|
6 and 12 months
|
Changes in generic health-related quality of life
Time Frame: 6 and 12 months
|
Change in Quality of Life score after 6 and 12 month measures by EQ-5D questionnaire. The EQ-5D-5L descriptive system comprises the five dimensions (MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT and ANXIETY / DEPRESSION), each dimension has five response levels: no problems, slight problems, moderate problems, severe problems, unable to /extreme problems. Responses are coded as single-digit numbers expressing the severity level selected in each dimension (1 - 5, where higher scores indicate more severe problems). The EQ VAS records the respondent's overall current health on a vertical visual analogue scale (0-100), where the endpoints are labelled 'The best health you can imagine - 100' and 'The worst health you can imagine - 0'. The EQ VAS provides a quantitative measure of the patient's perception of their overall health. |
6 and 12 months
|
HF-related mortality
Time Frame: 12 months
|
Rate of HF-related mortality
|
12 months
|
Cardiovascular Mortality
Time Frame: 12 months
|
Rate of cardiovascular mortality
|
12 months
|
All-cause Mortality
Time Frame: 12 months
|
Rate of all-cause mortality
|
12 months
|
Unplanned HF-related hospitalizations
Time Frame: 12 months
|
Rate of HF-related hospitalisations
|
12 months
|
Unplanned cardiovascular-related hospitalizations
Time Frame: 12 months
|
Rate of cardiovascular-related hospitalisations
|
12 months
|
Unplanned all-cause hospitalizations
Time Frame: 12 months
|
Rate of all-cause hospitalisations
|
12 months
|
Unplanned hospitalizations, other
Time Frame: 12 months
|
Number of days alive and out of hospital
|
12 months
|
Non-serious Adverse Events
Time Frame: 12 months
|
Rate of non-serious adverse events
|
12 months
|
Serious Adverse Events
Time Frame: 12 months
|
Rate of serious adverse events
|
12 months
|
Symptoms of heart failure
Time Frame: 12 months
|
Patient-reported symptoms of heart failure, measured by of the KCCQ Symptoms Score
|
12 months
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PASSPORT-HF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on CardioMEMSTM HF sensor - pulmonary artery pressure measurement
-
CardioMEMSCompletedHeart Failure, CongestiveUnited States
-
CardioMEMSCompletedNYHA Class III Heart FailureUnited States
-
Endotronix, Inc.Active, not recruitingHeart Failure NYHA Class IIIUnited States, Ireland, Belgium
-
Endotronix, Inc.Active, not recruiting
-
Northwestern UniversityGE HealthcareCompleted
-
Bicetre HospitalRecruitingARDS, Human | Ventilation Therapy; Complications | Alveolar; DisorderFrance
-
Endotronix, Inc.RecruitingHeart Failure NYHA Class II | Heart Failure NYHA Class IIIUnited States
-
Szeged UniversityUnknownHealthy Subjects | COPD Patients | Semi-supine Echo (SSE) | Flow-mediated Vasodilatation (FMD) | High Sensitive C-reactive Protein (hsCRP)Hungary
-
Inova Health Care ServicesAbbottRecruitingHeart Failure | Cardiogenic Shock | Ambulatory Hemodynamic MonitoringUnited States
-
University of ChileRecruiting